<!DOCTYPE html><html><head><meta charset='utf-8'><meta name='viewport' content='width=device-width, initial-scale=1'><script async src='https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-8422244967817077' crossorigin=anonymous'></script><link rel='stylesheet' href='/class.css'><script src='/script.js'></script></head><body><div class='topnav'></div><div class='list'><Br/><a href='4368.html'>//
//     Generate</a><Br/><a href='4369.html'>package hclwrite

</a><Br/><a href='4370.html'>In recent years, a</a><Br/><a href='4371.html'>Birth of Arianne K</a><Br/><a href='4372.html'>A prospective, coh</a><Br/><a href='4373.html'>Rachel Maddow repo</a><Br/><a href='4374.html'>As many of you kno</a><Br/><a href='4375.html'>Bangla

The Bangla</a><Br/><a href='4376.html'>Revealing insights</a><Br/><a href='4377.html'>There are various </a></div><div class='stats'><div class='logodiv'><a href='/'><img class='logoimg' src='/img/elephant.svg' /></a></div> <Br/><a href='4366.html'>The number of pati</a><Br/><a href='4365.html'>The long term goal</a><Br/><a href='4364.html'>Q:

Why does my ta</a><Br/><a href='4363.html'>Q:

Prove $\int_{x</a><Br/><a href='4362.html'>Q:

Android: How c</a><Br/><a href='4361.html'>/*
 * Copyright (c</a><Br/><a href='4360.html'>The first half of </a><Br/><a href='4359.html'>/**
 * Copyright (</a><Br/><a href='4358.html'>Q:

Javascript for</a><Br/><a href='4357.html'>"Hiding in the sha</a></div><div class='nav'><a href='4366.html'> << </a>&nbsp;&nbsp;&nbsp;&nbsp;<a href='4368.html'> >> </a></div><div class='article'>Synthesis and structure-activity relationships of dipeptoid amides as potent and selective nonpeptide antagonists of the human glucagon receptor.
We report here the design, synthesis, biological evaluation and structure-activity relationships of potent, selective and metabolically stable glucagon receptor antagonists. The screening data showed that the N-terminal tetrapeptoid 1 could be used as the model to replace the N-terminal dipeptide part of the natural hormone for glucagon receptor antagonists. Compound 15 with a spacer of 2 amino acid units of Glu-Ala in its structure had the highest binding affinity for the human glucagon receptor with a K(i) value of 0.2 nM and a selectivity of 6400-fold versus the human glucagon receptor as well as other related receptors such as the ghrelin receptor, the oxytocin receptor, the adrenocorticotropin receptor, the corticotropin-releasing factor receptor 1, the luteinizing hormone/choriogonadotropin receptor and the thyroid stimulating hormone receptor. Compound 15 is currently being developed for the treatment of type 2 diabetes.</div></body></html><!-- 2022-07-17 11:29:10 